Skip to main content

Advertisement

SpringerLink
Log in

The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer

Studies in patients with colorectal cancer, noncolonic neoplasms, and conditions predisposing to colorectal cancer

  • Published:
Diseases of the Colon & Rectum

Abstract

A specific macrophage migration inhibition assay, using patient lymphocytes incubated with a human colonic cancer extract, was studied in 92 patients with proven colorectal cancer and in 134 other individuals (20 normal controls, 80 patients with various nonmalignant gastrointestinal diseases, and 34 patients with extracolonic malignancies).

A positive response was obtained in 78 of 92 colorectal cancer patients, but in none of the 20 normal controls. A positive response occurred in four of 34 patients with extracolonic malignancies and in approximately half of patients with colonic adenomas and in one third of patients with ulcerative colitis. The significance of positive results in these patients (with diseases considered premalignant) is unclear, and is being studied further. In patients with previous resection of colorectal cancers, positive responses were frequent during the first year following resection, and rare thereafter.

The results suggest that this method may be useful as a clinical marker for colorectal cancer, and warrants further technical refinement and study of specific patient populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Cancer Society. Cancer facts and figures. New York: American Cancer Society, 1982.

    Google Scholar 

  2. Winawer SJ, Sherlock P. Surveillance before and after diagnosis and treatment of colorectal neoplasia. In: Alexander-Williams J, Binder HJ, eds. Large intestine. Boston: Butterworths, 1983:239–64.

    Google Scholar 

  3. Winawer SJ, Poleski MG, Sherlock P. Susceptibility for colorectal cancer: current concepts of screening, diagnosis and risk. In: Berk JE, ed. Developments in digestive diseases: clinical relevance. Philadelphia: Lea & Febiger, 1979:73–87.

    Google Scholar 

  4. Fath RB Jr, Winawer SJ: Early diagnosis of colorectal cancer. Ann Rev Med 1983;34:501–17.

    Article  PubMed  Google Scholar 

  5. Gilbertsen VA, McHugh R, Schuman L, Williams SE. The earlier detection of colorectal cancers: a preliminary report of the results of the occult blood study. Cancer 1980;45:2899–2901.

    Article  PubMed  CAS  Google Scholar 

  6. Gilbertsen VA. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer. Cancer 1974;34:936–9.

    Article  PubMed  Google Scholar 

  7. Zamcheck N. Current status of CEA. In: Winawer SJ, Schottenfeld D, Sherlock P, eds. Progress in cancer research and therapy. New York: Raven Press, 1980;13:219–34

    Google Scholar 

  8. Holt PG, Fimmel PJ, Finlay-Jones LM, Flower RL. Evaluation of the microplate leukocyte adherence inhibition test and its reproducibility, sensitivity, and relationship to other tests of cellular immunity. Cancer Res 1979;39:564–9.

    PubMed  CAS  Google Scholar 

  9. Helms RA, Bull DM. Natural killer activity of human lymphocytes against colon cancer cells. Gastroenterology 1980;78:738–44.

    PubMed  CAS  Google Scholar 

  10. Maluish AE, Halliday WJ. Hemocytometer leukocyte adherence inhibition technique. Cancer Res 1979;39:625–6.

    PubMed  CAS  Google Scholar 

  11. Ayeni AO, Thomson DM, MacFarlane JK, Daly D. A comparison of tube leukocyte adherence inhibition assay and standard physical methods for diagnosing colorectal cancer. Cancer 1981;48: 1855–62.

    Article  PubMed  CAS  Google Scholar 

  12. Hellström KE, Hellström I. The need to establish whether the leukocyte adherence inhibition test is a reliable assay of tumor immunity in humans. Cancer Res 1979;39:649–50.

    PubMed  Google Scholar 

  13. Morales A, Ottenhof PC. Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer 1983;52:667–70.

    Article  PubMed  CAS  Google Scholar 

  14. Leung KH, Koren HS. Regulation of human natural killing. J Immunol 1982;129:1742–7.

    PubMed  CAS  Google Scholar 

  15. Bull DM, Helm RA, Kushner LM. Natural killer (NK) activity against colon cancer cells: clinical correlations among normal individuals and patients with cancer and other diseases (abst.) Clin Res 1978;26:534A.

    Google Scholar 

  16. Adelman NE, Hammond ME, Cohen S, Dvorak HF. Lymphokines as inflammatory mediators. In: Cohen S, Pick E, Oppenheim JJ, eds. Biology of the lymphokines. New York: Academic Press, 1979:13–58.

    Google Scholar 

  17. Pick E, Cohen S, Oppenheim JJ. The lymphokine concept. In: Cohen S, Pick E, Oppenheim JJ, eds. Biology of the lymphokines. New York: Academic Press, 1979:1–12.

    Google Scholar 

  18. Zoller M, Schulz U, Dietze W, Wesch H, Matzku S. Postsurgical follow-up of colorectal cancer patients monitored by the leukocyte migration test. J Natl Cancer Inst 1983;70:581–7.

    PubMed  CAS  Google Scholar 

  19. Pick E. Mechanism of action of migration inhibitory lymphokines. In: Cohen S, Pick E, Oppenheim JJ, eds. Biology of lymphokines. New York: Academic Press, 1979:59–119.

    Google Scholar 

  20. Livni E, Gilon G, Shkolnik T, Cervaodio C. The significance of the macrophage migration inhibition factor test in patients with renal space occupying lesions (abstr). Tumour Biol 1984;5:101.

    Google Scholar 

  21. Yoshida T, Janeway CA Jr, Paul WE. Activity of migration inhibitory factor in the absence of antigen. J Immunol 1972;109:201–6.

    PubMed  CAS  Google Scholar 

  22. Szigeti R, Dalianis T, Ramqvist T, Ito Y, Klein G. Detection of mutant-specific responses by macrophage migration inhibition reactions induced by wild-type and mutant polyoma viruses and polyoma virus-infected cells. Cancer Res 1984;44:1077–80.

    PubMed  CAS  Google Scholar 

  23. Donskoy M, Forouhar F, Cohen MC. Lymphokine-induced migration inhibition of murine tumor cells derived from solid neoplasms. Cancer Res 1984;44:3870–2.

    PubMed  CAS  Google Scholar 

  24. Suslov I, McCoy JL, Herberman RB. Indirect leukocyte migration inhibition reactions to a 3-M KCl extract of lung adenocarcinoma by lung cancer patients. J Natl Cancer Inst 1981;66:233–7.

    PubMed  CAS  Google Scholar 

  25. Tripodi DS, Lyons S, Davies D. Separation of peripheral leukocytes by Ficoll density gradient centrifugation. Transplantation 1971;11:487–8.

    Article  PubMed  CAS  Google Scholar 

  26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–75.

    PubMed  CAS  Google Scholar 

  27. Turnbull RB Jr, Kyle K, Watson FR, Spratt J. Cancer of the colon: the colon: the influence of theno-touch isolation technic on survival rates. Ann Surg 1967;166:420–7.

    Article  PubMed  Google Scholar 

  28. Ablin RJ, Guinan PD, Bhatti RA. Cell-mediated immunity in prostatic cancer and its diagnostic relevancy. Eur J Cancer Clin Oncol 1983;19:467–71.

    Article  PubMed  CAS  Google Scholar 

  29. Thomson DM, Tataryn DN, Lopez M, Schwartz R, MacFarlane JK. Human tumor-specific immunity assayed by a computerized tube leukocyte adherence inhibition. Cancer Res 1979;39:638–43.

    PubMed  CAS  Google Scholar 

  30. Yoshida T, Bigazzi P, Cohen S. Biologic and antigenic similarity of virus-induced migration inhibition factor to conventional, lymphocyte-derived migration inhibition factor. Proc Natl Acad Sci USA 1975;72:1641–4.

    Article  PubMed  CAS  Google Scholar 

  31. Arends JW, Bosman FT, Hilgers J. Tissue antigens in large bowel carcinoma. Biochim Biophys Acta 1984;780:1–19.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Research Laboratories, Nahariya Regional Hospital, 22100, Nahariya, Israel

    Tamar Shkolnik Ph.D. & Ron Reshef M.D.

  2. Hematology Unit, Beilinson Medical Center, Petach Tikva

    Ella Livni Ph.D.

  3. the Gastroenterology Unit, Rambam Medical Center, Haifa, Israel

    Jesse Lachter M.D. & Shmuel Eidelman M.D.

Authors
  1. Tamar Shkolnik Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ella Livni Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ron Reshef M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jesse Lachter M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shmuel Eidelman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The abstract of this research has been accepted for presentation at the Sixth International Congress of Immunology, Toronto, Canada, July 6 to 11, 1986.

Supported by a grant from the Chief Scientist, Israel Ministry of Health.

About this article

Cite this article

Shkolnik, T., Livni, E., Reshef, R. et al. The macrophage migration inhibition (MIF) assay as a marker of colorectal cancer. Dis Colon Rectum 30, 101–105 (1987). https://doi.org/10.1007/BF02554942

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02554942

Key words

Search

Navigation